E-Cig Potential; Tapping the Brakes on AI; Cancer's Toll on Working Women

A review of 50 studies showed that e-cigarettes have the potential to increase smoking cessation as compared with nicotine patches, gum, and other alternatives, but more data are needed on long-term safety. (Cochrane Database of Systematic Reviews)

A phase III evaluation of copanlisib (Aliqopa) plus rituximab (Rituxan) met the primary endpoint of improved progression-free survival in relapsed indolent non-Hodgkin's lymphoma, Bayer announced.

Adding palbociclib (Ibrance) to standard endocrine therapy failed to improve invasive disease-free survival in women with early breast cancer and residual disease after neoadjuvant chemotherapy, the German Breast Group and Pfizer announced.

Urine-based DNA analysis outperformed traditional urine cytology for detection of bladder cancer. (American Association for Cancer Research)

A phase II trial of enfortumab vedotin-ejfv (Padcev) met the primary endpoint of objective response in previously treated, platinum-ineligible bladder cancer, Seagen and Astellas said in a joint announcement.

A preoperative immunotherapy combination showed early promise as a potential option for patients with localized bladder cancer that cannot be treated with cisplatin-based chemotherapy. (University of Texas MD Anderson Cancer Center, Nature)

Merck announced that the FDA expanded approval of pembrolizumab (Keytruda) to include adults with relapsed/refractory classical Hodgkin's lymphoma.

Tapping the brakes on AI: Researchers expressed concern about a possible lack of transparency in recent studies of artificial intelligence in healthcare settings, specifically interpretation of mammograms. (CUNY School of Public Health, Nature)

A third of young women with cancer said their disease significantly disrupted employment, and a fourth had to borrow money or declare bankruptcy. (University of North Carolina Chapel Hill, Cancer)

New insights into genetic and molecular characteristics of breast-tissue density and their association with breast cancer risk. (Icahn School of Medicine at Mount Sinai, Nature Communications)

Combining two types of targeted therapy led to objective responses in a fourth of patients with heavily treated relapsed/refractory Hodgkin's lymphoma in a preliminary clinical trial. (University of Texas MD Anderson Cancer Center, Clinical Cancer Research)

Comment